NAV

MW33

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
MW33
Accession Number
DB16358
Description

MW33 is a recombinant fully human antibody to SARS-CoV-2.2 This antibody injection is currently being investigated against COVID-19 in the clinical trial NCT04533048 (A Clinical Study to Evaluate MW33 Injection).

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • MW33

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action

The antibody MW33 targets the S protein epitope and is currently being investigated against COVID-19.1

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. DeFrancesco L: COVID-19 antibodies on trial. Nat Biotechnol. 2020 Nov;38(11):1242-1252. doi: 10.1038/s41587-020-0732-8. [PubMed:33087898]
  2. ClinicalTrials.gov: A Clinical Study to Evaluate MW33 Injection [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 16, 2020 13:46 / Updated on December 19, 2020 20:42